Clearmind Medicine (CMND) shares surged more than 84% premarket Tuesday after the company said it has received Institutional Review Board approval from Yale University for the phase 1/2a clinical trial of CMND-100 in alcohol use disorder.
The company said the approval brings it a step closer to starting the US Food and Drug Administration-regulated clinical program and further expands the multi-site trial.
According to Clearmind Medicine, the trial is designed to evaluate CMND-100's ability to reduce alcohol cravings and consumption among individuals with moderate to severe alcohol use disorder.
Price: 2.25, Change: +1.03, Percent Change: +84.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.